主要脂蛋白在IGF-1R抑制下的增加在Graves的轨道病:一个病例报告
Maxime Carpentier1, Pierre-Olivier Bertho2, Pierre Lebranchu3
1Nantes Université, CNRS, CHU Nantes, INSERM, l'institut du thorax, Nantes, France (Drs Carpentier, and Cariou); Nantes Université, CHU Nantes, Laboratoire de Biochimie Clinique, Nantes, France (Drs Carpentier and Bertho).
Journal of clinical lipidology
|August 6, 2025
概括
用teprotumumab治疗格雷夫斯轨道病的治疗可能会增加脂蛋白[Lp]水平,这是心血管风险因素. 在IGF-1抑制剂治疗期间,监测Lp (a) 是至关重要的,特别是在高危患者中.
科学领域:
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
背景情况:
- 升高的脂蛋白 (Lp) 是一个重要的心血管风险因素.
- 格雷夫斯病及其表现,格雷夫斯轨道病 (GO),涉及甲状腺刺激激素 (TSH) 和类似胰岛素的生长因子-1 (IGF-1) 信号传递.
- 通常情况下,IGF-1会使Lp (a) 水平降低40~80%.
研究的目的:
- 为了研究teprotumumab的作用,一个IGF-1受体抑制剂,在一个GO患者的Lp(a) 水平.
- 在GO治疗期间评估与改变Lp (a) 代谢相关的潜在心血管风险.
主要方法:
- 一个74岁的GO妇女的病例报告用teprotumumab治疗.
- 在治疗前和治疗期间监测血Lp (a) 度.
- 评估甲状腺平衡以排除其对Lp (a) 水平的影响.
主要成果:
- 患者经历了显著的Lp(a) 水平的增加,超过了异位性值 (> 125 nmol/L),在teprotumumab治疗后.
- Lp (a) 水平的变化与甲状腺平衡的变化无关.
- 采用teprotumumab治疗干扰了正常的IGF-1介导的Lp抑制.
结论:
- 通过teprotumumab抑制IGF-1受体可以导致Lp (a) 水平升高.
- 在GO患者接受IGF-1抑制剂治疗期间,对Lp (a) 的监测至关重要.
- 这强调了评估接受此类治疗的患者心血管风险的重要性.
相关概念视频
01:24Lipid Absorption
734
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
734
01:17Gastritis-II: Pathophysiology
548
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
548
01:24Glucagon-like Receptor Agonists
419
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
419
01:06Lipid Digestion
93.9K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
93.9K